A Phase I Open-Label, Multicenter, Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 30 Aug 2017 Planned End Date changed from 6 Jan 2018 to 3 Jul 2018.
- 12 Jul 2017 Planned End Date changed from 1 Dec 2016 to 6 Jan 2018.
- 06 Jun 2016 Number of treatment arms changed from 1 to 2.